期刊文献+

多发性骨髓瘤耐药机制相关研究进展:第55届美国血液学会年会报道 被引量:7

Advances in drug resistance mechanisms of multiple myeloma: reports from the 55th ASH annual meeting
原文传递
导出
摘要 多发性骨髓瘤是第二大血液系统恶性肿瘤,尽管新型药物层出不穷,但仍不可治愈.耐药是骨髓瘤复发和不可治愈的根源之一.文章就第55届美国血液学会(ASH)年会上有关多发性骨髓瘤耐药机制相关研究进展进行概述. Multiple myloma represents the second most common blood cancer.Although new drugs emerge rapidly,multiple myeloma is still incurable.Drug resistance is one of the main causes of myeloma recurrence and relapse.In this paper,advances about the drug resistance mechanisms reported in the 55th ASH annual meeting are summarized.
出处 《白血病.淋巴瘤》 CAS 2014年第3期133-136,共4页 Journal of Leukemia & Lymphoma
关键词 多发性骨髓瘤 耐药 美国血液学会年会 Multiple myeloma Drug resistance ASH annual meeting
  • 相关文献

参考文献30

  • 1Kyle RA, Rajkumar SV. Multiple myeloma[J]. Blood, 2008, 111: 2962-2972.
  • 2Pichiorri F, Suh SS, Ladetto M, et al. MicroRNAs regulate critical genes associated with multiple myeloma pathogenesis [J]. Proc Natl Acad Sci U S A, 2008, 105: 12885-12890.
  • 3Lonial S, Mitsiades CS, Richardson PG. Treatment options for relapsed and refractory multiple mycloma[J]. Clin Cancer Res, 2011, 17:1264- 1277.
  • 4Zhan F, Huang Y, Calla S, et al. The molecular classification of multiple myeloma[J]. Blood, 2006, 108: 2020-2028.
  • 5Nair B, van Rhee F, Shanghnessy JD, et al. Superior results of Total Therapy 3 (2003-33) in gene expression profiling-defined low-risk multiple myeloma confirmed in subsequent trial 2006-66 with VRD maintenance[J]. Blood, 201 O, 115:4168-4173.
  • 6Ye SQ, Qiang W, Chen Y, et al. MAF protein elicits innate resistance to bortezomib in multiple myeloma [J]. Blood (ASH Annual Meeting Abstracts), 2013, 122: 281.
  • 7Wang H, Baladandayuthapani V, Wang Z, et al. Expression of truncated protein tyrosine phosphatase, receptor type, O (PTPROt) influences multiple myeloma sensitivity to bortezomib through akt signaling, and is a favorable clinical prognostic factor[J]. Blood (ASH Annual Meeting Abstracts), 2013, 122: 2520.
  • 8Zhu YX, Braggio E, Shi CX, et al. Cereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomide[J]. Blood, 2~)11, 118: 4771-4779.
  • 9Neri P, Gratton K, Slaby LR, et al. RNA-sequencing of paired pre- treatment and relapse samples reveals differentially expressed genes associated with lenalidomide t~sistanee in multiple myeloma[J]. Blood (ASH Annual Meeting Abstracts), 2013, 122.
  • 10Pericole FV, Duarte ASS, Lazarini M, et al. Inflammasome and autophagy activation in symptomatic multiple myeloma could predict response to thalidomide-based chemotherapy[J]. Blood (ASH Annual Meeting Abstracts), 2013, 122: 3131.

同被引文献42

  • 1郎丽巍,王洪允,胡蓓,江骥.多不饱和脂肪酸在癌症及炎症疾病方面的研究进展[J].中国生化药物杂志,2014,34(1):153-155. 被引量:21
  • 2麦玉洁,李睿,邹德慧,王亚非,赵耀中,杨仁池,王建祥,肖志坚,韩明哲,钱林生,邱录贵.206例多发性骨髓瘤患者不同方案疗效分析[J].中华血液学杂志,2005,26(4):193-196. 被引量:37
  • 3黄幼生,苏琦,周秀田,苏坚,廖前进,解娜,葛玲.二烯丙基二硫对人结肠癌HT-29细胞G_1期的阻滞作用[J].中国药理学通报,2005,21(9):1128-1132. 被引量:9
  • 4Wilson A,Trumpp A.Bone-marrow haematopoietic-stem-cell niches[J].Nat Rev Immunol,2006,6:93-106.
  • 5He N,Zhang L,Cui J,et al.Bone marrow vascular niche:home for hematopoietic stem cells[J].Bone Marrow Res,2014,2014:128436.
  • 6Li L,Bhatia R.Stem cell quiescence[J].Clin Cancer Res,2011,17:4936-4941.
  • 7Li Z,Li L.Understanding hematopoietic stem-cell microenvironments[J].Trends Biochem Sci,2006,31:589-595.
  • 8Coskun S,Chao H,Vasavada H,et al.Development of the fetal bone marrow niche and regulation of HSC quiescence and homing ability by emerging osteolineage cells[J].Cell Rep,2014,9:581-590.
  • 9Lane SW,Scadden DT,Gilliland DG.The leukemic stem cell niche:current concepts and therapeutic opportunities[J].Blood,2009,114:1150-1157.
  • 10Ishikawa F,Yoshida S,Saito Y,et al.Chemotherapy-resistant human AML stem cells home to and engraft within the bone-marrow endosteal region[J].Nat Biotechnol,2007,25:1315-1321.

引证文献7

二级引证文献18

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部